Concourse Financial Group Securities’s Emergent Biosolutions EBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-6
Closed -$33 2335
2023
Q2
$44 Hold
6
﹤0.01% 2316
2023
Q1
$62 Buy
+6
New +$73 ﹤0.01% 2342
2022
Q3
Sell
-56
Closed -$1.56K 2123
2022
Q2
$2K Sell
56
-75
-57% -$2.56K ﹤0.01% 2015
2022
Q1
$5K Sell
131
-57
-30% -$2.51K ﹤0.01% 1846
2021
Q4
$8K Hold
188
﹤0.01% 1911
2021
Q3
$9K Buy
188
+157
+506% +$9.51K ﹤0.01% 1909
2021
Q2
$2K Sell
31
-77
-71% -$4.95K ﹤0.01% 2177
2021
Q1
$10K Sell
108
-627
-85% -$64.2K ﹤0.01% 1766
2020
Q4
$66K Buy
735
+250
+52% +$22.9K 0.01% 1061
2020
Q3
$50K Sell
485
-95
-16% -$10.2K ﹤0.01% 1060
2020
Q2
$46K Buy
580
+92
+19% +$6.86K ﹤0.01% 1022
2020
Q1
$28K Sell
488
-49
-9% -$2.82K ﹤0.01% 1110
2019
Q4
$29K Buy
537
+283
+111% +$15.3K ﹤0.01% 1138
2019
Q3
$13K Sell
254
-31
-11% -$1.44K ﹤0.01% 1078
2019
Q2
$14K Sell
285
-1,780
-86% -$85.3K ﹤0.01% 1376
2019
Q1
$104K Sell
2,065
-183
-8% -$10.8K 0.01% 675
2018
Q4
$133K Buy
2,248
+2,065
+1,128% +$133K 0.02% 548
2018
Q3
$12K Buy
+183
New +$10.7K ﹤0.01% 1033

Other funds holding EBS

Concourse Financial Group Securities's EBS Position: Q3 2023 in Review

Concourse Financial Group Securities sold out of Emergent Biosolutions (EBS) in Q3 2023, closing a stake of 6 shares — an estimated $33 sold.

Concourse Financial Group Securities first reported a position in EBS in Q3 2018 and held it in 18 quarters. The position peaked at $133K in Q4 2018. 161 funds tracked by Wall St. Rank hold EBS as of Q3 2023.

  • Concourse Financial Group Securities reported no remaining Emergent Biosolutions position as of Q3 2023 after selling out during the quarter.
  • Concourse Financial Group Securities sold 6 Emergent Biosolutions shares in Q3 2023, an estimated $33.
  • Concourse Financial Group Securities first reported a position in Emergent Biosolutions in Q3 2018 and held it in 18 quarters.
  • Concourse Financial Group Securities's Emergent Biosolutions position peaked at $133K in Q4 2018.
  • 161 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2023.

Based on Concourse Financial Group Securities's 13F filing for Q3 2023, filed 25 Oct 2023.